

# Laboratory Services Our roots... our future.



## Report

A lab is a lab is a lab. The process, whether we're testing patients, drugs or consumer products, remains the same: **sample, test, report.** It's how we've grown our business in the past, by providing reliable and consistent results. It's how we'll continue to grow it in the future.



**WARNEX**  
First Quarter 2010

## Management's Discussion and Analysis

Management's discussion and analysis provides a review of the performance of our Company and should be read in conjunction with the unaudited financial statements for the quarter ended March 31, 2010, and the related notes appearing elsewhere in this document. This discussion and analysis compares the performance for the first quarter of 2010 with that of 2009 and also discloses additional information to help better understand our business. This includes a review of the opportunities, issues, and risks that may impact future operations. Information contained herein includes any significant developments as at May 11, 2010, the date on which the MD&A was approved by the Company's Board of Directors.

The enclosed financial statements have been prepared in accordance with the Canadian generally accepted accounting principles (GAAP). All figures are in Canadian dollars unless otherwise indicated.

Additional information relating to our Company, including the Annual Information Form (AIF), is available on SEDAR at [www.sedar.com](http://www.sedar.com).

### Forward-Looking Statements

Certain statements contained in this Management's Discussion and Analysis are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk and Uncertainties Section of this Management's Discussion and Analysis. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

### Overview

Warnex is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario. The Company's common stock is traded on the Toronto Stock Exchange, under the symbol WNX.

In June 2009, the Company acquired the shares of Molecular World Inc. and subsequently changed its name to Warnex PRO-DNA Services Inc. The operations of this subsidiary are included in the Medical Laboratories division.

## Strategic Business Units

Our operations are organized into these strategic business units:

Business Unit	Activity
Analytical Services	Provides quality control services to the pharmaceutical and biotechnology industries, including chemistry, chromatography, microbiology, method development and validation, and stability studies. This includes assessing the physical, chemical and microbiological properties of individual ingredients in addition to verifying the active ingredient content of finished products.
Bioanalytical Services	Assists both innovator and generic pharmaceutical companies as well as biotechnology companies in their development of new pharmaceutical products by conducting bioavailability and bioequivalence studies as part of clinical trials.
Medical Laboratories	Provides specialized laboratory testing services to the healthcare and pharmaceutical sectors, including the Prenatest <sup>®</sup> prenatal screening test. This division also offers genetic testing, pharmacogenetic services and human DNA identification including forensic DNA testing.

## Corporate Highlights

### Operating Highlights

- Warnex's Medical Laboratories division was recognized for quality laboratory services. Warnex Medical Laboratories has met all criteria for the renewal of its Laboratory Accreditation by COLA, a U.S. healthcare accreditation organization. Accreditation is given only to laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey. COLA standards meet or exceed requirements under CLIA (Clinical Laboratory Improvement Amendments).
- Warnex's CEO, Mark Busgang, participated in Quebec Premier Jean Charest's economic mission to India from January 31 to February 6, 2010. During the Mission Québec-India 2010, Mr. Charest was accompanied by the Minister of Economic Development, Innovation and Export Trade, Mr. Clément Gignac, the Minister of International Relations, Mr. Pierre Arcand, as well as a delegation of 130 participants from industry, academia, research and innovation sectors. The Mission Québec-India 2010 made stops in Mumbai, Bangalore and New Delhi. Warnex already has several very important customers in India and Mr. Busgang was exploring additional business opportunities in this market, which has a significant pharmaceutical and clinical research industry.

### Balance Sheet

- Total assets of \$14.6 million and shareholders' equity of \$2.7 million
- \$52.7 thousand invested in property, plant and equipment
- \$64.9 thousand invested in computer software
- Cash and cash equivalents of \$0.3 million
- \$0.5 million used from the \$2.0 million short-term bank financing facility

### Statement of Earnings and Comprehensive Income

- Revenue of \$5.1 million (2009 - \$7.6 million)
- Net loss of \$0.8 million (2009 - net earnings of \$1.1 million)

- Net loss of \$0.01 per share (2009 - net earnings of \$0.02 per share)
- Adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA), as defined in the financial performance section of this report, of \$(0.3) million (2009 - \$1.9 million)

### Management Objectives

Our goal is to create value for our shareholders by building a strong suite of profit-generating pharmaceutical and medical laboratory services. Below are our objectives for 2010.

#### 2010 Objectives

- Attain profitability by increasing revenues, managing costs and improving productivity
- Restructure our balance sheet
- Increase business development effort in all divisions to increase revenue and expand our geographic markets
- Evaluate new business opportunities, including strategic acquisitions, to expand our service offering and increase critical mass

### Financial Performance

#### Results of Operations for the Three Months Ending March 31, 2010, Compared to the Three Months Ending March 31, 2009

The following table provides selected financial data from the unaudited financial statements:

	Revenue			Net earnings (net loss)		
	Q1 2010 \$	Q1 2009 \$	Variance \$	Q1 2010 \$	Q1 2009 \$	Variance \$
Analytical	2,867,902	2,764,763	103,139	329,025	114,175	214,850
Bioanalytical	895,767	3,590,866	(2,695,099)	(519,695)	1,881,995	(2,401,690)
Medical	1,268,966	1,126,120	142,846	273,178	231,713	41,465
Management services	58,035	75,906	(17,871)	(879,672)	(1,125,126)	245,454
<b>Total</b>	<b>5,090,670</b>	<b>7,557,655</b>	<b>(2,466,985)</b>	<b>(797,164)</b>	<b>1,102,757</b>	<b>(1,899,921)</b>


For the three-month period ended March 31, 2010, revenue reached \$5,090,670 (2009 - \$7,557,655), a decrease of 33% compared to last year. The Analytical and Medical divisions generated combined revenue growth of 6% this year while the Bioanalytical division had a 75% reduction compared to last year.

The Analytical division's revenues increased by 4% from \$2.8 million in 2009 to \$2.9 million in 2010. The analytical laboratory in Laval generated \$1.2 million during the quarter (2009 - \$1.2 million) while the Neopharm division in Blainville generated \$1.7 million (2009 - \$1.6 million). This increase is a result of our continued efforts in business development.

The Bioanalytical division's revenues decreased by 75% from \$3.6 million in 2009 to \$0.9 million in 2010. This decrease is partly due to the postponement of several studies to the second quarter as well as the Bioanalytical division's extraordinary performance in the first quarter of 2009 due to the execution and completion of several complex projects at higher prices. Our business development efforts in this division are ongoing to increase our business from new and existing customers.

The Medical division's revenue increased by 13% from \$1.1 million in 2009 to \$1.3 million in 2010. Prenatal testing revenues increased by 6% and molecular diagnostics increased by 47%, while pharmacogenetic contracts decreased by 32% compared to last year. The acquisition of Molecular World Inc., concluded on June 12, 2009, provided revenues of \$0.2 million for the quarter ended March 31, 2010.

The proportion of revenues generated by Canadian customers increased to 74% in 2010 from 51% in 2009. The proportion of revenues from U.S. customers decreased to 19% in 2010 from 38% in 2009 and from foreign customers decreased to 7% in 2010 from 11% in 2009. The proportion of total revenue generated in U.S. dollars was lower than last year, with 17% in 2010 versus 46% in 2009.



Gross margin for the three-month period ended March 31, 2010, amounted to \$782,919 or 15% of revenue (2009 - \$3,067,532 or 41% of revenue). The decrease of \$2,284,613 in gross margin is mainly explained by the lower revenue in the Bioanalytical division compared to last year as well as the execution of high margin projects in this division during the first quarter of 2009.

Selling, administrative, and financial expenses as well as research and development tax credits are summarized as follows:

	Q1 2010	Q1 2009	Variance
	\$	\$	\$
Selling and administrative	1,535,832	1,481,504	54,328
Financial	276,556	310,939	(34,383)
Research and development tax credits	(88,000)	-	(88,000)
<b>Total</b>	<b>1,724,388</b>	<b>1,792,443</b>	<b>(68,055)</b>

Selling and administrative expenses amounted to \$1,535,832 for the three-month period ended March 31, 2010 (2009 - \$1,481,504). The increase of \$54,328 is mainly explained by a loss on foreign exchange due to the strength of the Canadian dollar compared to the U.S. dollar and the increased investment in our sales group, despite a reduction in other expenses compared to last year. In proportion of revenue, administrative and selling expenses were higher than last year at 30% (2009 - 20%).

Financial expenses decreased by \$34,383, from \$310,939 in the first quarter of 2009 to \$276,556 in the first quarter of 2010, mainly due to less interest following repayments made on the long term debt.

For the three-month period ended March 31, 2010, net loss amounted to \$797,164 or \$0.01 per share (2009 - net earnings of \$1,102,757 or \$0.02 per share).

For the three-month period ended March 31, 2009, adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) amounted to \$(319,839) (2009 - \$1,912,975), a decrease of \$2,232,814. This decrease is mainly due to lower revenue and margins in the first quarter of 2010 compared to 2009.

Adjusted EBITDA is a non-GAAP financial measure and does not have any standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. The calculation for the period under review is as follows:

	Q1 2010	Q1 2009	Variance
	\$	\$	\$
Net earnings (loss)	(797,164)	1,102,757	(1,899,921)
Financial expenses	276,556	310,939	(34,383)
Interest revenue	(2,567)	(5,822)	3,255
Amortization	366,579	397,351	(30,772)
Unrealized foreign exchange loss (gain) on debentures	(144,305)	172,332	(316,637)
Unrealized foreign exchange loss (gain) on working capital components	22,066	(64,617)	86,683
Compensation for stock options	(41,004)	35	(41,039)
<b>Adjusted EBITDA</b>	<b>(319,839)</b>	<b>1,912,975</b>	<b>(2,232,814)</b>

For the adjusted EBITDA calculation, the Company now includes the unrealized gains and/or losses on foreign exchange.

### Balance Sheet

The balance sheet as at March 31, 2010, shows total assets of \$14.6 million (December 2009 - \$15.5 million), working capital of \$(0.5) million (December 2009 - \$0.4 million), shareholders' equity of \$2.7 million (December 2009 - \$3.6 million), cash of \$0.3 million (December 2009 - \$0.9 million) and a bank indebtedness of \$0.5 million (December 2009 - \$nil). In 2010, the Company also invested \$52.7 thousand in property, plant and equipment and \$64.9 thousand in computer software.

Summary of Quarterly Results


The following tables provide selected quarterly information regarding the Statement of Earnings:

	Revenue			Net earnings (loss)		
	2010 \$	2009 \$	2008 \$	2010 \$	2009 \$	2008 \$
Q1	5,090,670	7,557,655	6,141,566	(797,164)	1,102,757	(286,322)
Q2		5,421,474	5,858,423		(346,660)	1,520,417*
Q3		4,656,405	6,669,833		(782,797)	511,610
Q4		6,011,453	7,116,899		(137,548)	627,352
Total		23,646,987	25,786,721		(164,248)	2,373,057*

\*Includes a gain on extinguishment of debt of \$1,814,192.

	Net earnings (loss) per share			Diluted net earnings (loss) per share		
	2010 \$	2009 \$	2008 \$	2010 \$	2009 \$	2008 \$
Q1	(0.01)	0.02	(0.01)	(0.01)	0.01	(0.01)
Q2		(0.01)	0.03		(0.01)	0.02
Q3		(0.01)	0.01		0.00	0.01
Q4		0.00	0.01		0.00	0.01
Total		0.00	0.04		0.00	0.03

Revenue per quarter



## Liquidity and Capital Resources

The commercial operations of Warnex's service divisions have been financed through their own internally generated cash flows, the use of commercial banking facilities, debentures and capital leases with equipment vendors.

In May 2008, the Company extinguished its debt in the principal amount of \$11,345,000 with the existing debenture holders. The Company then entered into new agreements with the same lenders which included the following terms and conditions:

- Elimination of the fixed conversion rate of 1.369 contained in the US dollar denominated debentures, therefore reducing the principal debt from CDN\$6,845,000 to US\$5,000,000;
- Conversion of an aggregate of \$1,830,200 in principal into common shares of Warnex;
- Repayment of an aggregate of \$1,333,333 in principal upon closing;
- An aggregate of \$6,333,333 in principal to be paid in three years;
- Increase in the interest rate on the US dollar denominated debentures to 12% per annum;
- Reduction in the exercise price of 3,963,729 warrants to \$0.25 and the extension of the term of 1,570,983 warrants by two years.

In 2008, the Company issued 12,343,316 common shares at \$0.15 each in connection with the conversion of debentures.

In June 2008, a non-secured convertible debenture holder converted \$15,000 into 100,000 common shares at a price of \$0.15 each.

In August and September 2009, a non-secured convertible debenture holder converted \$120,000 into 800,000 common shares at a price of \$0.15 each.

The Company entered into an agreement with Desjardins Group for financing and banking services as announced on May 6, 2008. As part of the agreement, Warnex received financing facilities totalling \$4 million, which include a revolving line of credit of \$2 million and term debt of \$2 million. The proceeds of this financing were used to repay certain debentures and the existing term debt with the National Bank of Canada, as well as for general working capital purposes. In June 2009, the Company received a new term loan of \$350,000, which was used in the Molecular World Inc. acquisition.

In June 2009, The Company renewed its financing facility which remained unchanged except for the financial covenants.

As of December 31, 2009, the Company was not in compliance with the working capital ratio and the annual debt service coverage covenants contained in the credit facility. As of March 31, 2010, the Company is not in compliance with the working capital ratio covenant contained in the credit facility. The lender has continued to waive compliance with these covenants as at these dates.

With the reorganization of our balance sheet, the Company intends to pursue its business plan and finance its planned growth through internally generated funds. If the growth is faster than anticipated or if we make acquisitions, we may then require additional capital.

The Board of Directors of Warnex has implemented an investment policy regulating the investment activities of cash resources. The Company invests, if necessary, solely in liquid, high-grade securities with varying maturity dates. As at March 31, 2010, the Company had \$0.3 million invested in cash (December 2009 - \$0.9 million) and had used \$0.5 million of the line of credit (December 2009 - \$nil). The Company does not invest in asset backed commercial paper.

The following table provides the contractual obligations for the next five years:

<b>Payments due by period</b>	Less than 1 year \$	1 - 3 years \$	4 - 5 years \$	More than 5 years \$
Long-term debt <sup>(1)</sup>	861,183	279,368	-	-
Capital lease obligations	538,921	276,565	-	-
Operating leases <sup>(2)</sup>	717,781	1,471,101	1,463,521	2,009,067
Purchase obligations	45,590	53,508	-	-
Non-convertible debenture	-	838,600	-	-
Convertible debentures <sup>(3)</sup>	-	5,434,201	-	-
<b>Total</b>	<b>2,163,475</b>	<b>8,353,343</b>	<b>1,463,521</b>	<b>2,009,067</b>

Note 1: As of March 31, 2010, the Company did not meet a covenant contained in the agreement with its banker. As a result, all of the bank term loans are being included in the current liabilities.

Note 2: Operating leases of more than 5 years consist mainly of lease contracts for the buildings until 2018.

Note 3: The convertible debentures may be converted into Warnex shares at or before their maturity.

Note 4: The Company does not engage in off-balance sheet arrangements.

### Related Party Transactions

During the period, the Company paid \$1,000 per month for a total of \$3,000 (2009 - \$3,000), to the Company's Chairman of the Board for his work on specific mandates for the various operating divisions of the Company.

These transactions are measured at the exchange amount, which is the amount of consideration determined and agreed to by the related parties. The Company has a policy that the non-related members of the Board of Directors must approve any related party transaction.

### Critical Accounting Estimates

The \$1.0 million of goodwill results from the acquisition of PRO-DNA Diagnostics Inc. in May 2006. The Company assesses on an ongoing basis, and at least annually, whether a provision for permanent impairment in the value of goodwill should be adjusted to earnings. No adjustment was required as at March 31, 2010.

### Future Accounting Changes

#### International Financial Reporting Standards

In February 2008, the Canadian Accounting Standards Board (AcSB) confirmed that publicly accountable enterprises will be required to transition from Canadian GAAP to International Financial Reporting Standards ("IFRS") for interim and annual financial reporting purposes for fiscal years beginning on or after January 1, 2011, with comparative information.

The Company has established a changeover plan that consists primarily of three phases: assessment, planning, and implementation. An external advisor has been engaged to work closely with the Company's staff to complete the changeover to IFRS. The Company's management has been receiving training from this advisor and this training is expected to continue throughout the transition on an as-needed basis. The Board of Directors and Audit Committee have also received IFRS information.

The assessment phase includes the identification of significant differences between the Company's existing Canadian GAAP and IFRS that are relevant to the Company and a high-level review of the alternatives available upon adoption. This phase was completed during 2009.

The planning phase includes identification, evaluation and selection of accounting policies necessary for the Company to transition from Canadian GAAP to IFRS as well as potential first-time adoption exemptions. This phase was initiated in the second half of 2009. The Company is currently in the process of finalizing this phase. This phase involves assessing the impact of the transition on the data system and internal control over financial reporting, and disclosure controls and procedures. It also involves assessing the further training required for the financial team and the impact on business activities such as capital requirements, banking agreements or compensation arrangements.

The implementation phase will integrate all the solutions into the Company's financial system and processes that are necessary for the Company to convert to IFRS.

To date, the transition process has identified the following significant accounting issues:

<b>Key Accounting Areas</b>	<b>Identified Differences with Potential Impact to the Company</b>
Presentation of financial statements	<ul style="list-style-type: none"> <li>▪ Additional disclosures in the notes to the financial statements.</li> <li>▪ Presentation of financial statements will change, however the Company has not yet decided on the most appropriate presentation.</li> </ul>
Property, plant and equipment	<ul style="list-style-type: none"> <li>▪ Evaluating impact of componentization on accounting policy: all significant components of property and equipment will be amortized accordingly to their useful lives determined in accordance with IFRS.</li> <li>▪ Evaluating impact of different recognition and measurement principles, including but not limited to amortization policies and residual values.</li> <li>▪ The Company is still compiling the data required to identify required adjustments, if any.</li> </ul>
Impairment of assets	<ul style="list-style-type: none"> <li>▪ Grouping of assets in cash-generating units (CGUs) on the basis of independent cash inflows for impairment testing purposes, using a Fair Value or Value-in-Use (i.e. discounted cash-flow method (DCF)) approach.</li> <li>▪ Goodwill will then be allocated to and tested in conjunction with its related CGU or group of CGUs.</li> <li>▪ The Company is currently in the process of defining a CGU.</li> </ul>
Revenue	<ul style="list-style-type: none"> <li>▪ Analysing whether the Company measures revenue at fair value, whether identifiable components are required to be recognized, whether revenue from services is recorded using the percentage of completion method.</li> <li>▪ The Company has preliminarily determined that no change is required to measure revenue at fair value, that no identifiable components are required to be identified, and that no material change will be realized as a result of recognizing all revenue using the percentage of completion method. However, as a result of the evaluation, the Company plans to modify its information systems in order to satisfy revenue measurement in accordance with IFRS.</li> </ul>
Leases	<ul style="list-style-type: none"> <li>▪ The Company has reviewed all existing lease agreements and preliminarily determined that no adjustments are required.</li> </ul>
Share-based payments	<ul style="list-style-type: none"> <li>▪ Compensation expense for a share-based payment award issued to non-employees should be measured at the fair value of services received. Forfeitures shall not subsequently be reversed if the vested equity instruments are later forfeited or, in the case of share options, the options are not exercised.</li> <li>▪ The Company is currently evaluating the impact of these differences.</li> </ul>

Provisions	<ul style="list-style-type: none"> <li>▪ Different threshold used for recognition of a contingent liability, which could have an impact on timing of when a provision may be recorded.</li> <li>▪ The Company is currently evaluating the impact of this difference.</li> </ul>
------------	---

Furthermore, the Company has identified the following significant IFRS 1 optional exemptions that will likely be selected:

Business combinations exemption	IFRS 1 provides the option to apply IFRS 3, Business Combinations, retrospectively or prospectively from the Transition Date. The retrospective basis would require restatement of all business combinations that occurred prior to the Transition Date. The Company has initially decided to elect not to retrospectively apply IFRS 3 to business combinations that occurred prior to its Transition Date and such business combinations will not be restated. Any goodwill arising on such business combinations before the Transition Date will not be adjusted from the carrying value previously determined as a result of applying this exemption.
Share-based payments exemption	IFRS 2, Share-based Payments, encourages application of its provisions to equity instruments granted on or before November 7, 2002, but permits the application only to equity instruments granted after November 7, 2002 that had not vested by the Transition Date. The Company has initially decided to elect to avail itself of the exemption provided under IFRS 1 and applied IFRS 2 for all equity instruments granted after November 7, 2002, that had not vested by its Transition Date.

The Company currently has not finalized its selection of IFRS accounting policies or the selection of IFRS 1 exemptions available upon transition but expects to finalize these selections by the end of the second quarter of 2010. The Company will continue to make progress on its changeover plan as well as monitor the standards development as issued by both the IASB and the AcSB and expects to finalize the planning phase by the end of the first half of 2010 and commence the third phase of transition thereafter.

The Company does not expect to realize any significant business impacts, or significant changes to its internal controls over financial reporting as a result of the IFRS transition. The Company does expect to modify its IT systems to accommodate the changeover however, this modification is expected to be minimal. This assessment may change as the Company continues to evolve during its transition to IFRS.

As the Company's transition activities progress, disclosures of IFRS, as issued by the IASB implementation accounting policy differences are expected to increase. The Company will also ensure that its key stakeholders are informed about the anticipated effects of the IFRS transition. In the current year, the Company is providing IFRS information through its public disclosure documents to highlight such anticipated effects on the Company.

The Company will present its results for fiscal 2010 using Canadian GAAP. In 2011, the Company will present its comparative results for fiscal 2010 using IFRS as issued by the IASB effective at that time. To accomplish this, in 2010 the Company will track any adjustments required to its accounting records in order to effect its reconciliations from Canadian GAAP to IFRS.

### Capital disclosures

The Company's objective when managing capital is to maintain adequate cash resources to support planned activities which include providing analytical, bioanalytical and medical laboratory services. The Company includes shareholders equity, cash, short-term investments and long term debt in the definition of capital. The Company currently has debt owing to the trade accounts payable, the bank, and the holders of the long-term debt and debentures.

The Company's objective when managing capital is also to maintain financial flexibility in order to preserve its ability to meet financial obligations, including debt servicing payments. Accordingly, the

Company had entered into agreements with various lending institutions as described in notes 8, 9 and 10 of the financial statements.

In managing capital, the Company estimates its future cash requirements by preparing a budget and a multiyear plan annually for review and approval by the Company's Board of Directors. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multiyear plan estimates future activity along with the potential cash requirements and is based on the Company's assessment of its current services along with the expected results from the coming year's activity. Budget to actual variances are prepared monthly and reviewed by the Company's management and are presented quarterly to the Board.

Historically, funding for the Company's plan has been primarily managed through the issuance of additional common shares, common share purchase warrants that upon exercise are converted to common shares, and the issuance of various debt instruments. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with the Company's progress through its programs, general market conditions, and the availability of capital. There are no assurances that funds will be made available to the Company when required.

### Outstanding Share Data

As at the date of this report, the nominal and fully diluted numbers of shares are as follows:

	<b>Nominal</b>	<b>Fully diluted</b>
Issued and outstanding common shares	67,117,191	67,117,191
Options issued	869,229	869,229
Share warrants <sup>(1)</sup>	3,570,983	3,570,983
Convertible debentures <sup>(2)</sup>	\$1,500,000	2,500,000
U.S. convertible debentures <sup>(3)</sup>	US\$4,000,000	14,300,000
<b>Total</b>		<b>88,357,403</b>

Note 1: 1,570,983 share warrants expire in June 2011 and the balance in October 2011.

Note 2: The conversion rates are \$0.50 and \$0.75 for each tranche of \$750,000 of the principal amount.

Note 3: The conversion rates of the debentures are \$0.15, \$0.20, \$0.25, \$0.50 and \$0.75 for each tranche of US\$800,000 of the principal amount. In June 2008, 100,000 common shares at \$0.15 each were issued in connection with a debenture conversion. In August and September 2009, 800,000 common shares at \$0.15 each were issued in connection with debenture conversions.

In May 2008, the Company extinguished its debt in the principal amount of \$11,345,000 with the existing debenture holders. The Company then entered into new agreements with the same lenders which included the following terms and conditions:

- Elimination of the fixed conversion rate of 1.369 contained in the US dollar denominated debentures, therefore reducing the principal debt from CDN\$6,845,000 to US\$5,000,000;
- Conversion of an aggregate of \$1,830,200 in principal into common shares of Warnex;
- Repayment of an aggregate of \$1,333,333 in principal upon closing;
- An aggregate of \$6,333,333 in principal to be paid in three years;
- Increase in the interest rate on the US dollar denominated debentures to 12% per annum;
- Reduction in the exercise price of 3,963,729 warrants to \$0.25 and the extension of the term of 1,570,983 warrants by two years.

As part of these new agreements, the Company issued warrants as follows:

- For the debentures totalling \$905,100, warrants were issued to the lenders entitling the purchase of 392,746 shares until June 25, 2009, and 2,000,000 shares until October 24, 2011, for a total of 2,392,746 common shares at a price of \$0.25 per share.
- For the debentures totalling \$4,842,734, warrants were issued to the lenders entitling the purchase of 1,570,983 common shares until June 25, 2011, at a price of \$0.25 per share.

On June 12, 2009, the Company issued 2,000,000 common shares of Warnex for the acquisition of Molecular World Inc.

## **Financial Disclosure**

### Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to provide reasonable assurance that material information required to be disclosed by us is recorded, processed, summarized and reported within the time periods specified under Canadian securities laws, and include controls and procedures that are designed to ensure that information is accumulated and communicated to management, including the President and Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure.

As of March 31, 2010, an evaluation was carried out, under the supervision of and with the participation of management, including the President and Chief Executive Officer and the Chief Financial Officer, of the design of our disclosure controls and procedures as defined under National Instrument 52-109. Based on that evaluation, the President and Chief Executive Officer and the Chief Financial Officer concluded that the disclosure controls and procedures were properly designed as at March 31, 2010.

### Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

As of March 31, 2010, management evaluated the design of internal control over financial reporting as defined under National Instrument 52-109, and based on that evaluation determined that certain aspects of internal control over financial reporting were not designed effectively. The control deficiencies identified by the Company did not result in adjustments to our interim consolidated financial statements for 2010. Management's assessment identified the following material weaknesses:

- Entity level controls

The Company did not maintain a completely effective control environment as defined in accordance with COSO control framework. Specifically, we do not have comprehensive procedure manuals to clearly communicate management's and employees' roles and responsibilities in the Company's internal control over financial reporting.

To mitigate the risk, management relies on automated controls mainly relating to the implementation of a new accounting system, as well as manual procedures and detection controls, weekly management meetings, monthly reviews of financial statements by the operating divisions and quarterly reviews of financial statements by the Audit Committee. These procedures were performed during the first quarter of 2010.

- Information technology general controls

The Company did not adequately maintain effective control over ensuring that the backup tapes are periodically tested to verify their accuracy. In addition, there is no information technology strategic plan

and business continuity plan and no periodic review performed on the security logs for failed logins. Also, the Company did not adequately maintain effective controls over program development and program changes.

- Period-end financial reporting process

The Company did not maintain effective controls over ensuring that certain account balances requiring the use of accounting estimates are reviewed by a person other than the preparer. The Company consults with its external auditor when necessary.

- Income Taxes

The Company did not maintain effective controls over the recording of income taxes payable and the income tax provision. The Company is currently relying on its external auditor to ensure correctness of the above mentioned items.

- Segregation of duties

The Company had deficient controls within its accounting and finance department over segregation of duties inherent to its size. Specifically, as a result of the limited number of personnel in the accounting and finance department, certain financial personnel had incompatible duties that allowed for the creation, review and processing of certain financial data without independent review and authorization.

To mitigate the risk, management relies on automated controls mainly relating to the implementation of a new accounting system, as well as, manual procedures and detection controls, weekly management meetings, monthly reviews of financial statements by the operating divisions and quarterly reviews of financial statements by the Audit Committee. These procedures were performed during the first quarter of 2010.

#### Remediation of material weaknesses in internal control over financial reporting

Subsequent to March 31, 2010, we have begun or plan to take the following actions to address the material weaknesses in internal controls over financial reporting identified as of March 31, 2010. Management and the Audit Committee have taken an active role in responding to the deficiencies identified, including overseeing management's implementation of the remedial measures described below.

- Entity level controls

We will finalize and distribute procedure manuals which communicate management's and employees' roles and responsibilities.

- Information technology general controls

We will implement enhanced information technology policies and procedures specifically with regards to system's change management, program development, program changes, IT operations and related monitoring. We will develop and implement a global information technology strategic plan and a business continuity plan.

In the beginning of 2009, management administered the implementation of a new accounting system. This new system introduced automated controls into the accounting system process and replaced certain manual controls that management had to rely upon. This major step ensured more rigorous monitoring of controls over access to the accounting system.

- Period-end financial reporting process

We will continue to develop controls over the period-end financial reporting process where feasible. As the Company grows, we plan to expand the number of individuals involved in the financial close

process and enhance the level of accounting knowledge. We intend to add one additional person in the accounting department.

Since 2009, the new accounting system improved the period-end financial reporting process by replacing certain manual procedures with automated procedures. We introduced new controls such as, ensuring access to certain accounting spreadsheets was restricted to the appropriate personnel, implemented a disclosure checklist to ensure compliance with GAAP, and implemented a review process for the consolidation and complex journal entries by a person other than the preparer.

- **Income taxes**

We will continue to consult with our third party expert advisors on a regular basis for tax advices. As the Company grows, we will plan to expand the number of individuals involved in the accounting function and enhance the level of tax knowledge.

- **Inadequate segregation of duties**

We will continue to employ appropriate measures to restrict or independently monitor systems access and/or properly assign job roles and responsibilities to employees to ensure the proper segregation of duties where feasible. As the Company grows, we will expand the number of individuals involved in the accounting function. For the coming year, we will add one additional person in the accounting department.

Management realizes that some of the above weaknesses are inherent to a company of our size. Nevertheless, we believe in and are committed to establishing rigorous disclosure controls and procedures and internal control over financial reporting. It will take time to put in place the rigorous controls and procedures desired by our management and our Board of Directors. We cannot at this time estimate how long it will take to complete the steps identified above. Our management will continue to evaluate the design of our overall control environment and will continue to refine existing controls as they, in conjunction with the Audit Committee of our Board of Directors, Chief Executive Officer and Chief Financial Officer, think necessary. Again, the control deficiencies identified by the Company did not result in adjustments to our interim consolidated financial statements for 2010.

Other than the remediation efforts discussed above and the implementation of Warnex' internal controls over financial reporting, there have been no changes in our internal control over financial reporting that occurred since the beginning of fiscal year 2010 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting. Our management, including our Chief Executive Officer and our Chief Financial Officer, have discussed these issues and remediation efforts in detail with the Audit Committee of our Board of Directors.

The Company will provide updates on the remediation plan in its quarterly reports and its annual MD&A.

## **Risk and Uncertainties**

### Financial Resources

Warnex believes that it should be able to obtain long-term capital, if necessary, to support its corporate objectives. Please refer to the liquidity and capital resources section for additional comments. However, it is impossible to guarantee the availability of additional financial resources or that these will be available under acceptable conditions. Our cash requirements may vary materially depending on various factors, including changes in the number of customers and the volume of work ordered in our service divisions.

### Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company manages liquidity risk by forecasting cash flows to identify financing

requirements by maintaining committed and demand credit facilities and by maintaining access to additional financing at competitive rates through capital markets and highly rated financial institutions.

#### Key Customers and Business Partners

Warnex Analytical's two most important customers accounted for 37% of sales for the year 2009 (2008 - 38%). These customers have remained Warnex Analytical's largest customers in each of its sites for many years and we consider that our relationships with them are good. Warnex Bioanalytical's three main customers accounted for 53% of this division's revenues for the year 2009 (2008 - 57%) and we consider that our relationships with these important customers are good. The loss of any of these customers could adversely affect our financial results.

#### Credit Risk

Financial instruments, which potentially subject Warnex to concentrations of credit risk, consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are maintained with high-credit quality financial institutions. Consequently, management considers the risk of non-performance related to cash and cash equivalents to be minimal. The Company, in the normal course of business, monitors the financial condition of its customers and reviews the credit history of each new customer. The Company establishes an allowance for doubtful accounts that corresponds to the credit risks of its specific customers, historical trends and economic circumstances. Individual overdue accounts are reviewed and allowance adjustments are recorded when determined necessary to state receivables at the realizable value. If the financial conditions of customers deteriorate, resulting in their diminished ability or willingness to make payment, additional provisions for doubtful accounts are recorded. The Company's maximum credit risk exposure corresponds to the carrying amounts of the accounts receivable.

#### Foreign Currency Risk

The Company realizes some of its revenues in U.S. dollars and Euros and some of its purchases and interest payments on the convertible debentures in U.S. dollars. Consequently, we are exposed to fluctuations of these currencies.

#### Government Regulations

The provision by Warnex of its analytical, bioanalytical and medical laboratories services is governed by numerous statutes and regulations. The subject-matter of this legislation includes Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), the Therapeutic Products Directorate (TPD) and other standards and permits required to operate our laboratories. Findings of important non-compliance to such regulations, or important modifications to statutes and regulations governing Warnex's activities, could affect the ability or the conditions upon which the Company carries out services, and could have an adverse effect on results.

#### Laboratory Facilities

The Company relies on having properly validated, fully functioning laboratory facilities in which to render its services. Should systems fail, or a disaster strike, the ability to render services would be negatively affected which, in turn, would affect revenue generation. The Company does not currently have backup solutions for all the equipment used for rendering services. As a result, should an unexpected event as described above occur, our results could be adversely affected.

#### Volatility of Share Price

The market price of Warnex shares is subject to volatility because of different factors, including reports on new information and deviations in actual financial or scientific results as compared to expectations of

shareholders and securities analysts who follow our activities. In addition, the shares of Warnex, of other life sciences companies and of the stock market in general have been subject to fluctuations, which were unrelated to the operations or results of the Company. There is no guarantee that the market price of Warnex's shares will be protected from all such fluctuations in the future.

### Employees

Warnex's continued success will be dependent on the performance and continued service of certain key employees. The loss of any of these individuals could have a material adverse impact on the Company's business. We believe that our success relies in part on our ability to continue attracting and retaining such competent employees.

### Suppliers

Warnex is dependant on third parties for the supply of certain specialized reagents. Although Warnex looks to secure alternative suppliers, Warnex may not be able to obtain the reagents or products from such third parties, the reagents or products may not comply with specifications, the prices at which Warnex purchases them may increase or Warnex may not be able to locate alternative sources of supply in a reasonable time period. Should any of these events occur, Warnex may not be able to continue to market certain of its services which could adversely affect our results.

### **Outlook**

We expect to generate profits and a positive EBITDA, as defined in the financial performance section, and improve our financial results compared to 2009.

Signed for management, this 11<sup>th</sup> day of May 2010.



Mark Busgang  
President & CEO



François Jetté, CA  
Chief Financial Officer

## Interim Consolidated Balance Sheets (Unaudited)

	March 31 2010	December 31 2009
<b>Assets</b>		
<b>Current</b>		
Cash and cash equivalents	\$301,617	\$894,031
Accounts receivable (note 5)	3,333,181	2,880,919
Work-in-progress	122,463	531,142
Inventory	160,457	177,027
Investment tax credits receivable	563,000	712,471
Prepaid expenses	496,591	388,502
	<b>4,977,309</b>	<b>5,584,092</b>
<b>Future income taxes</b>	<b>1,221,000</b>	<b>1,221,000</b>
<b>Property, plant and equipment</b> (note 6)	<b>7,083,261</b>	<b>7,375,516</b>
<b>Intangible assets</b> (note 7)	<b>425,453</b>	<b>382,145</b>
<b>Goodwill</b>	<b>937,695</b>	<b>937,695</b>
	<b>\$14,644,718</b>	<b>\$15,500,448</b>
<b>Liabilities</b>		
<b>Current</b>		
Bank indebtedness (note 8)	\$460,000	\$-
Accounts payable	2,884,102	3,008,594
Deferred revenue	520,195	411,599
Current portion of long-term debt (note 9)	1,614,019	1,800,372
	<b>5,478,316</b>	<b>5,220,565</b>
<b>Long-term debt</b> (note 9)	<b>291,050</b>	<b>447,661</b>
<b>Liability component of debentures</b> (note 10)	<b>6,126,572</b>	<b>6,245,274</b>
	<b>11,895,938</b>	<b>11,913,500</b>
<b>Shareholders' equity</b>		
Capital stock (note 11)	40,981,049	40,981,049
Equity component of debentures (note 10)	312,288	312,288
Contributed surplus	2,425,012	2,466,016
Deficit	(40,969,569)	(40,172,405)
	<b>2,748,780</b>	<b>3,586,948</b>
	<b>\$14,644,718</b>	<b>\$15,500,448</b>

The accompanying notes are an integral part of these consolidated financial statements.

### Interim Consolidated Statements of Contributed Surplus (Unaudited)

For the three months ended March 31	2010	2009
Balance, beginning of period	<b>\$2,466,016</b>	\$2,445,043
Stock-based compensation	<b>(41,004)</b>	35
<b>Balance, end of period</b>	<b>\$2,425,012</b>	\$2,445,078

The accompanying notes are an integral part of these consolidated financial statements.

### Interim Consolidated Statements of Deficit (Unaudited)

For the three months ended March 31	2010	2009
Balance, beginning of period	<b>\$(40,172,405)</b>	\$(40,008,157)
Net earnings (loss)	<b>(797,164)</b>	1,102,757
<b>Balance, end of period</b>	<b>\$(40,969,569)</b>	\$(38,905,400)

The accompanying notes are an integral part of these consolidated financial statements.

### Interim Consolidated Statements of Accumulated Other Comprehensive Income (Unaudited)

For the three months ended March 31	2010	2009
<b>Accumulated Other Comprehensive Income</b>	<b>\$-</b>	\$-

The accompanying notes are an integral part of these consolidated financial statements.

### Interim Consolidated Statements of Earnings and Comprehensive Income (Unaudited)

For the three months ended March 31	2010	2009
<b>Revenue</b>	<b>\$5,090,670</b>	\$7,557,655
<b>Cost of goods sold</b> (note 12)	<b>4,307,751</b>	4,490,123
<b>Gross margin</b>	<b>782,919</b>	3,067,532
<b>Operating expenses</b> (note 12)		
Selling, general and administrative	1,535,832	1,481,504
Finance charges	276,556	310,939
Research and development tax credits	(88,000)	-
	<b>1,724,388</b>	1,792,443
<b>Earnings (loss) before under noted item and income taxes</b>	<b>(941,469)</b>	1,275,089
<b>Unrealized foreign exchange gain (loss) on debentures</b>	<b>144,305</b>	(172,332)
<b>Earnings (loss) before income taxes</b>	<b>(797,164)</b>	1,102,757
<b>Income taxes</b>	-	300,000
<b>Recovery of income taxes due to utilization of prior years' losses</b>	-	(300,000)
	-	-
<b>Net earnings (loss) and comprehensive income</b>	<b>\$(797,164)</b>	\$1,102,757
<b>Basic net earnings (loss) per share</b>	<b>\$(0.01)</b>	\$0.02
<b>Fully diluted net earnings (loss) per share</b>	<b>\$(0.01)</b>	\$0.01
<b>Weighted average number of shares outstanding</b>	<b>67,117,191</b>	64,317,191
<b>Weighted average number of fully diluted shares outstanding</b>	<b>67,117,191</b>	88,876,998

The accompanying notes are an integral part of these consolidated financial statements.

## Interim Consolidated Statements of Cash Flows (Unaudited)

For the three months ended March 31	2010	2009
<b>Operations</b>		
Net earnings (loss)	\$(797,164)	\$1,102,757
Items not affecting cash:		
Amortization of property, plant and equipment	345,000	382,243
Amortization of intangible assets	21,579	15,108
Accretion of interest	25,603	22,253
Unrealized foreign exchange loss (gain) on debentures	(144,305)	172,332
Foreign currency fluctuation	24,026	(31,141)
Compensation cost for stock options	(41,004)	35
	<b>(566,265)</b>	1,663,587
Net change in non-cash working capital items (note 13)	<b>(23,645)</b>	(403,682)
Net cash provided by (used in) operations	<b>(589,910)</b>	1,259,905
<b>Investing activities</b>		
Acquisition of property, plant and equipment	(52,745)	(135,847)
Acquisition of intangible assets	(64,887)	(95,486)
Net cash used in investing activities	<b>(117,632)</b>	(231,333)
<b>Financing activities</b>		
Increase in operating line of credit	460,000	-
Repayment of long-term debt	(342,964)	(383,383)
Net cash provided by (used in) financing activities	<b>117,036</b>	(383,383)
<b>Foreign exchange gain (loss) on cash held in foreign currencies</b>	<b>(1,908)</b>	43,170
<b>Increase (decrease) in cash and cash equivalents</b>	<b>(592,414)</b>	688,359
<b>Cash and cash equivalents, beginning of period</b>	<b>894,031</b>	2,433,488
<b>Cash and cash equivalents, end of period</b>	<b>\$301,617</b>	\$3,121,847

The accompanying notes are an integral part of these consolidated financial statements.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**1. Description of business and basis of financial statement presentation**

Warnex Inc. is incorporated under the laws of Canada. Warnex is a life sciences company devoted to protecting public health by providing diverse laboratory services. The Company offers analytical, bioanalytical and medical laboratory services to the pharmaceutical and healthcare sectors. The Company's common stock is traded on the Toronto Stock Exchange, under the symbol WNX.

The Company's consolidated financial statements have been prepared in accordance with Canadian generally accepted accounting principles and include the accounts of the Company and all of its subsidiaries: Warnex Analytical Services Inc., Warnex PRO-DNA Services Inc., and Warnex America Inc. All amounts are presented in Canadian dollars, unless otherwise indicated.

On June 12, 2009, the Company purchased the shares of Molecular World Inc. On June 30, 2009, the Company changed the name of Molecular World Inc. to Warnex PRO-DNA Services Inc.

These consolidated financial statements have been prepared in accordance with Canadian generally accepted accounting principles (GAAP) on a going concern basis, which presumes the Company will continue in operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business for the foreseeable future. These consolidated financial statements do not include any adjustments to amounts and classifications of assets and liabilities should the Company not be able to continue as a going concern.

**2. Changes in accounting policies and significant accounting policies****Changes in accounting policies****Goodwill and intangible assets**

In February 2008, the CICA issued Handbook section 3064, *Goodwill and Intangible Assets*, replacing Handbook Sections 3062, *Goodwill and Other Intangible Assets* and 3450, *Research and Development Costs and Emerging Issues Committee (EIC) Abstract 27, Revenues and Expenditures during the Pre-Operating Period*. Section 3064 establishes standards for the recognition, measurement, presentation and disclosure of goodwill subsequent to its initial recognition and intangible assets by profit-oriented enterprises. This new standard became effective January 1, 2009. There is no material impact on the Company's financial statements in adopting this new standard.

**Credit Risk and Fair Value of Financial Assets and Financial Liabilities**

In January 2009, the CICA issued EIC Abstract 173, *Credit Risk and the Fair Value of Financial Assets and Financial Liabilities*. The EIC requires the Company to take into account the Company's own credit risk and the credit risk of the counterparty in determining the fair value of financial assets and financial liabilities, including derivative instruments. There is no material impact on the Company's financial statements in adopting this new standard.

**Financial Instruments Disclosures**

In May 2009, the CICA amended Section 3862, *Financial Instruments – Disclosures*, to include additional disclosure requirements about fair market value measurements for financial instruments and liquidity risk disclosures. These amendments require a three-level hierarchy that reflects the significance of the inputs used in making the fair value measurements. Fair values of assets and liabilities included in Level 1 are determined by reference to quoted prices in active markets for identical assets and liabilities. Assets and liabilities in Level 2 include valuations using inputs other than quoted prices for which all significant outputs are observable, either directly or indirectly. Level 3 valuations are based on inputs that are unobservable and significant to the overall fair value measurement. The application of this amendment did not materially impact the Company.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**2. Changes in accounting policies and significant accounting policies... cont'd****Significant accounting policies**

These financial statements have been prepared by management in accordance with Canadian generally accepted accounting principles. The most significant accounting policies are summarized below.

**Interim financial statements**

The accompanying unaudited financial statements are prepared in accordance with Canadian generally accepted accounting principles for interim financial statements and do not include all the information required for complete financial statements. They are consistent with the policies outlined in the Company's audited financial statements for the year ended December 31, 2009. The interim financial statements and related notes should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2009. When necessary, the financial statements include amounts based on informed estimates and best judgments of management. The results of operations for the interim periods reported are not necessarily indicative of results to be expected for the year.

**Use of estimates**

The preparation of financial statements in conformity with Canadian generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as well as the disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions also affect revenues and expenses during the reported period. Actual results could differ from these estimates.

**Revenue recognition**

Analysis revenue from analytical and medical laboratory services is recorded at the time the test is completed. Project revenue from these services is recorded using the percentage of completion method whereby revenue and profit are based on ratio of costs incurred to total estimated costs of the projects.

Revenue from bioanalytical services is recorded using the percentage of completion method whereby revenue and profit are based on a ratio of costs incurred to total estimated costs of the project.

Costs and estimated profit on contracts in progress in excess of amounts billed are reflected as work-in-progress. Cash received in advance of revenues being recognized on contracts is classified as deferred revenue.

The Company monitors its contracts with customers on a regular basis to determine if a loss is likely to occur. If a loss is anticipated on a contract, the entire estimated loss is recorded as a reduction of revenue and work-in-progress in the period in which the loss becomes evident and reasonably estimable.

**Cash and cash equivalents**

Cash and cash equivalents consist of bank accounts and short-term investments with maturity dates of three months or less.

**Inventory**

Inventory is valued at the lower of cost and net realizable value. Cost is determined on the first-in first-out basis.

**Research and development tax credits**

The Company uses the accrual method of accounting to charge research and development tax credits to earnings. These tax credits arise as a result of incurring qualified scientific research and development expenditures.

## Notes to Interim Consolidated Financial Statements (unaudited)

March 31, 2010 and 2009

### 2. Changes in accounting policies and significant accounting policies...cont'd

#### Investment tax credits

The Company claims investment tax credits as a result of incurring scientific research and experimental development expenditures. Investment tax credits are recognized when the related expenditures are incurred and there is reasonable assurance of their realization. Management has made a number of estimates and assumptions in determining the expenditures eligible for the investment tax credit claim. It is possible that the allowed amount of the investment tax credit claim could be materially different from the recorded amount upon assessment by the tax authorities.

#### Future income taxes

The Company follows the liability method with respect to accounting for income taxes. Future tax assets and liabilities are determined based on differences between the carrying amount and the tax basis of assets and liabilities. Future income tax assets and liabilities are measured using the enacted income tax rates that will be in effect when these differences are expected to reverse. Future income tax assets, if any, are recognized only to the extent that, in the opinion of management, it is more likely than not the assets will be realized.

#### Property, plant and equipment

Property, plant and equipment are recorded at cost and amortized over their estimated useful life or over the term of the lease as follows:

Declining-balance method		
Lab equipment		20%
Machinery and equipment		20%
Computer equipment		30%
Furniture, fixtures and telephone equipment		20%
Non-refundable government financial assistance		20%
Straight-line method		
Leasehold improvements		over the terms of the leases

Non-refundable government financial assistance regarding property, plant and equipment are netted against these assets when earned.

#### Intangible assets and goodwill

Computer software is recorded at cost and amortized on the declining balance method at a rate of 20%. Licences and customer lists are recorded at cost and amortized over their estimated useful lives, not exceeding 5 years. Goodwill represents the excess of the purchase price over the fair value of the net assets acquired. Goodwill and intangible assets with indefinite life are subject to at least an annual assessment for impairment by applying a fair value test. The Company then assesses whether a provision for permanent impairment in the value of goodwill should be adjusted to earnings. This is determined mainly by analyzing whether the projected discounted cash flows exceed the net book value of goodwill.

#### Impairment of long-lived assets

Long-lived assets, which comprise property, plant and equipment, and intangible assets with definite life, are reviewed for impairment when certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable i.e. when their net book value exceeds the sum of the undiscounted cash flows expected to result from their use and eventual disposition. An impairment loss should be recognized when the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The impairment amount is measured as the amount by which the carrying amount of the asset exceeds its fair value, calculated using discounted cash flows when quoted market prices are not available.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**2. Changes in accounting policies and significant accounting policies... cont'd****Debentures**

The value of the debt component of the debentures has been determined, at the time of their issuance, by discounting the future capital and interest payments until their maturity dates at a discount rate which represented the borrowing rate available to the Company for similar debentures having no warrants or conversion rights. The remaining portion of the net proceeds of the debentures issued is presented as part of shareholders' equity. The difference between the principal amount of the debentures and the liability component carrying amount at inception is accreted to the face value of each debenture through the recording of additional interest expense over the term of the debenture through periodic charges to income using the effective interest rate method of amortization.

**Deferred revenue**

In the bioanalytical services and medical laboratory services divisions, deferred revenue represents the difference between the amount invoiced to customers as per each customer agreement and the revenue recognized. Furthermore, the medical laboratory services may have deferred revenue consisting of the amount received from customers as prepayments for services to be rendered in the future.

**Earnings (loss) per share**

Earnings (loss) per share are calculated using the weighted average number of shares outstanding during the period. Diluted earnings (loss) per share are computed using the treasury stock method, giving effect to the exercise of all stock options, share warrants and convertible debentures. The diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of these elements.

**Foreign exchange**

The Company follows the temporal method to translate its foreign currency balances and transactions into Canadian dollars. Monetary items on the balance sheet are translated at the exchange rates in effect at the end of the period, while non-monetary items are translated at the historical rates of exchange. Revenues and expenses are translated at the rates of exchange in effect on the transaction date or at the average exchange rates for the period. Gains or losses resulting from the translation are included in earnings for the period.

**Stock option plan**

The fair value of stock options is evaluated on the grant date using the Black-Scholes model. The cost is recognized on a straight-line basis over the vesting period of the options as an increase to the compensation expense and to contributed surplus. Upon exercise of these stock options, the cash proceeds received and the amount previously credited to contributed surplus related to the exercised options are credited to common share paid-up capital.

**Financial instruments**

The Company establishes the classification of financial instruments at their initial recognition. Financial assets are classified as held for trading, available for sale, held to maturity or loans and receivables. Financial liabilities are classified as held for trading or other liabilities.

Subsequent measurement and recognition of changes in fair value of financial instruments depend on their initial classification. Held for trading financial instruments are measured at fair value and all gains and losses are included in net income in the period in which they arise. Available-for-sale financial instruments are measured at fair value with revaluation gains and losses included in other comprehensive income until the assets are removed from the balance sheet.

The standards also require derivative instruments to be recorded as either assets or liabilities measured at their fair value unless exempted from derivative treatment as a normal purchase and sale. Certain derivatives embedded in other contracts must also be measured at fair value. All changes in the fair value of derivatives are recognized in earnings unless specific hedge criteria are met, which requires that a company must formally document, designate and assess the effectiveness of transactions that receive hedge accounting.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**3. Future accounting changes****International Financial Reporting Standards**

In February 2008, the Canadian Accounting Standards Board (AcSB) has confirmed that effective for interim and annual financial statements related to fiscal years beginning on or after January 1, 2011, International Financial Reporting Standards ("IFRS") will replace Canada's current Generally Accepted Accounting Principles for all publicly accountable profit-oriented enterprises. The Company is currently evaluating the impact of this changeover on its consolidated financial statements.

**Business combinations**

In January 2009, the CICA issued Handbook Section 1582, *Business Combinations*, which requires that all assets and liabilities of an acquired business will be recorded at fair value at acquisition. Obligations for contingent considerations and contingencies will also be recorded at fair value at the acquisition date. The standard also states that acquisition-related costs will be expenses as incurred and that restructuring charges will be expensed in periods after the acquisition date. The new standard applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period on or following January 1, 2011. The Company will assess the impact of this new standard at the time of any applicable acquisitions.

**Consolidations and Non-Controlling Interests**

In January 2009, the CICA issued Handbook Section 1601, *Consolidations*, and Section 1602, *Non-Controlling Interests*. Section 1601 establishes standards for the preparation of consolidated financial statements. Section 1602 establishes standards for accounting for a non-controlling interest in a subsidiary in consolidated financial statements subsequent to a business combination. These standards apply to interim and annual consolidated financial statements relating to fiscal years beginning on or after January 1, 2011. The Company is currently assessing the impact of this new standard on its financial statements.

**4. Business acquisition**

On June 12, 2009, the Company acquired all of the issued and outstanding shares of Molecular World Inc., a laboratory located in Thunder Bay, Ontario, specializing in human DNA identification including forensic DNA testing. The acquisition was accounted for using the purchase method. The purchase price was paid by the issuance of 2,000,000 common shares of Warnex with a fair value of \$310,000. The net assets acquired at the attributed values were: \$82,996 of short-term assets; \$471,000 of future income taxes; \$345,372 of property, plant and equipment; \$2,530 of computer software; \$38,936 of customer lists; assumption of short-term liabilities of \$343,989, and long-term debt of \$286,845.

The operations of this subsidiary are included in the Medical Laboratories division.

**5. Accounts receivable**

	March 31, 2010 \$	December 31, 2009 \$
Trade	3,346,293	2,925,847
Allowance for doubtful accounts	(45,588)	(45,588)
	3,300,705	2,880,259
Sundry	32,476	660
	3,333,181	2,880,919

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**6. Property, plant and equipment**

March 31, 2010	Cost \$	Accumulated Amortization \$	Net \$
Lab equipment	13,538,729	8,472,196	5,066,533
Machinery and equipment	113,004	28,294	84,710
Computer equipment	830,782	624,220	206,562
Furniture, fixtures and telephone equipment	503,159	376,615	126,544
Leasehold improvements	5,725,150	3,954,344	1,770,806
Non-refundable government financial assistance	(465,000)	(293,106)	(171,894)
	<u>20,245,824</u>	<u>13,162,563</u>	<u>7,083,261</u>
December 31, 2009	Cost \$	Accumulated Amortization \$	Net \$
Lab equipment	13,514,056	8,206,749	5,307,307
Machinery and equipment	113,004	23,835	89,169
Computer equipment	808,647	607,717	200,930
Furniture, fixtures and telephone equipment	503,159	369,166	133,993
Leasehold improvements	5,719,213	3,894,155	1,825,058
Non-refundable government financial assistance	(465,000)	(284,059)	(180,941)
	<u>20,193,079</u>	<u>12,817,563</u>	<u>7,375,516</u>

The above includes lab equipment under capital lease having a cost of \$1,599,039 (December 2009 - \$1,599,039) and a net carrying value of \$1,144,969 (December 2009 - \$1,205,230), and computer equipment under capital lease having a cost of \$37,439 (December 2009 - \$37,439) and a net carrying value of \$29,815 (December 2009 - \$32,232).

**7. Intangible assets**

March 31, 2010	Cost \$	Accumulated Amortization \$	Net \$
Licences	33,380	17,246	16,134
Customer lists	38,936	9,734	29,202
Computer software	854,448	474,331	380,117
	<u>926,764</u>	<u>501,311</u>	<u>425,453</u>
December 31, 2009	Cost \$	Accumulated Amortization \$	Net \$
Licences	33,380	15,577	17,803
Customer lists	38,936	6,489	32,447
Computer software	789,561	457,666	331,895
	<u>861,877</u>	<u>479,732</u>	<u>382,145</u>

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**8. Financing facility**

The Company has the following credit facilities which are renewed annually with the bank:

- i) \$2,000,000 operating line of credit which is due on demand and bears interest at 2% over the bank's prime lending rate;
- ii) \$2,000,000 bank loan, due May 2011, bearing interest at 2.25% over the bank's prime lending rate and repayable by monthly instalments of \$55,556 plus interest; and
- iii) \$350,000 bank loan, due June 2012, bearing interest at 2.25% over the bank's prime lending rate and repayable by monthly instalments of \$9,722 plus interest.

The Company and its subsidiaries have provided as security for the facilities a first ranking moveable hypothec in the amount of \$6,000,000 covering the universality of tangible and intangible moveable properties, present and future.

The credit facility requires the following financial covenants to be met:

- i) Quarterly working capital ratio of 1.25:1;
- ii) Quarterly debt to tangible net worth ratio of 2:1; and
- iii) Annual debt service coverage ratio of a minimum of 1.25:1.

In June 2009, the Company renewed its financing facility which remained unchanged except for the financial covenants, as indicated above.

As at March 31, 2010, the Company is not in compliance with the working capital ratio covenant contained in the credit facility. The lender has waived compliance with this covenant.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**9. Long-term debt**

	March 31 2010 \$	December 31 2009 \$
Business Development Bank of Canada (BDC) term loan, due April 2011, bearing interest at 2% over the BDC's floating rate, repayable by monthly instalments of \$3,300, plus interest and secured by a general security agreement providing for a first charge on all equipment, furniture and fixtures of Warnex PRO-DNA Services Inc.	42,900	52,800
Bank term loan, due May 2011, bearing interest at 2.25% over the bank's prime lending rate, repayable by monthly instalments of \$55,556 plus interest and secured as described in note 8. The Company did not meet its covenants contained in the agreement with its banker. As a result, the bank term loan is being included in the current portion.	777,777	944,444
Bank term loan, due June 2012, bearing interest at 2.25% over the bank's prime lending rate, repayable by monthly instalments of \$9,722 plus interest and secured as described in note 8. The Company did not meet its covenants contained in the agreement with its banker. As a result, the bank term loan is being included in the current portion.	262,500	291,667
6.6% obligation under capital lease, due June 2011, repayable by monthly instalments of \$17,955 principal and interest. This obligation is secured by specific equipment having a carrying value of \$402,199	257,800	306,856
8.5% obligation under capital lease, due November 2011, repayable by monthly instalments of \$25,750 principal and interest. This obligation is secured by specific equipment having a carrying value of \$742,770	478,616	544,758
9.4% obligation under capital lease, due April 2012, repayable by monthly instalments of \$686 principal and interest. This obligation is secured by specific equipment having a carrying value of \$16,574	15,511	17,177
9.4% obligation under capital lease, due June 2012, repayable by monthly instalments of \$519 principal and interest. This obligation is secured by specific equipment having a carrying value of \$13,241	12,591	13,832
Canada Economic Development interest-free loan up to a maximum amount of \$153,000 or 40% of approved expenses to assist in export market development, repayable in eight equal consecutive semi-annual payments commencing March 2008	57,374	76,499
	1,905,069	2,248,033
Current portion	1,614,019	1,800,372
	291,050	447,661

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**10. Debentures**

	March 31 2010 \$	December 31 2009 \$
<hr/> \$500,000 non-secured non-convertible debenture, bearing interest at a rate of 12% annually maturing June 2, 2011. Also, as part of this financing, share warrants were issued entitling the lender to purchase 2,000,000 common shares of the Company for a price of \$0.25 a share until October 24, 2011.	500,000	500,000
US\$4,000,000 non-secured convertible debentures, bearing interest at a rate of 12% annually maturing June 25, 2011, and convertible into 15,200,000 common shares of the Company at the sole option of the lender. The conversion rates of the debentures are \$0.15, \$0.20, \$0.25, \$0.50 and \$0.75 for each tranche of US\$800,000 of the principal amount. Also, as part of this financing, share warrants were issued entitling the lender to purchase 1,570,983 common shares of the Company for a price of \$0.25 a share until June 25, 2011.	3,934,201	4,070,531
US\$333,333 non-secured non-convertible debenture, bearing interest at a rate of 12% annually maturing June 25, 2011. Also, as part of this financing, share warrants were issued entitling the lender to purchase 392,746 common shares of the Company for a price of \$0.25 a share until June 25, 2009.	338,600	350,333
\$1,500,000 non-secured convertible debenture bearing interest at a rate of 12% annually maturing July 9, 2011, and convertible into 2,500,000 common shares of the Company at the sole option of the lender. The conversion rates are \$0.50 and \$0.75 for each tranche of \$750,000 of the principal amount.	1,500,000	1,500,000
<hr/>		
Discount on debentures	6,272,801	6,420,864
Current portion of debentures	(146,229)	(175,590)
	-	-
<hr/>		
	<u>6,126,572</u>	<u>6,245,274</u>

The nominal and effective interest rates are as follows:

	Nominal	Effective
<hr/> \$500,000 maturing June 2, 2011	12.0%	14.0%
US\$4,000,000 maturing June 25, 2011	12.0%	14.0%
US\$333,333 maturing June 25, 2011	12.0%	14.0%
<hr/> \$1,500,000 maturing July 9, 2011	<u>12.0%</u>	<u>14.0%</u>

In August and September 2009, a non-secured convertible debenture holder converted \$120,000 into 800,000 common shares at a price of \$0.15 each.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**11. Capital stock**

## a) Authorized

An unlimited number of the following classes of shares:

Preferred shares, issuable in series, without nominal or par value.

Common shares, voting, without nominal or par value.

## b) Issued and fully paid common shares

	March 31, 2010		December 31, 2009	
	Number	Amount \$	Number	Amount \$
Balance, beginning of period	67,117,191	40,981,049	64,317,191	40,551,049
Issuance of shares	-	-	2,800,000	430,000
Balance, end of period	67,117,191	40,981,049	67,117,191	40,981,049

In June 2009, the Company issued 2,000,000 common shares at \$0.155 each for the acquisition of Molecular World Inc., as described in note 4.

In August and September 2009, the Company issued 800,000 common shares at \$0.15 each in connection with a debenture conversion as described in note 10.

## c) Stock option plan

The Company has in place an Incentive Stock Option Plan. The Plan provides that the terms of the options and the option price shall be fixed by the Board of Directors, subject to the price restrictions imposed by the Exchange. The stock options are granted only to directors, officers, consultants, employees and other key personnel of the Company or its subsidiaries and only upon the recommendation of the Board of Directors of the Company.

The maximum number of common shares that are issuable under the Plan cannot exceed 4,319,273, i.e. 10% of the number of outstanding common shares at the time when the plan was amended.

Stock options granted under the Incentive Stock Option Plan may not be for a period longer than 10 years and the exercise price must be paid in full upon exercise. During 2003, in order to comply with the Exchange requirements, the Company amended its stock option plan changing the period from 5 years to 10 years.

On September 17, 2008, the Board of Directors revised the Company's stock option plan for employees and decided not to grant any more stock options to employees, excluding directors and officers, which is at the discretion of management. As a result, the Company cancelled 123,000 options.

As at March 31, 2010, the Company has granted options to purchase 869,229 (December 2009 - 869,229) common shares at various exercise prices, each pursuant to the Incentive Stock Option Plan of the Company, expiring no later than the year 2019.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**11. Capital stock... cont'd**

The changes to the number of stock options outstanding are as follows:

	March 31, 2010		December 31, 2009	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Balance, beginning of period	869,229	0.61	884,898	0.87
Granted	-	-	233,331	0.15
Exercised	-	-	-	-
Cancelled	-	-	(249,000)	1.08
Balance, end of period	869,229	0.61	869,229	0.61
Exercisable at the end of period	869,229	0.61	869,229	0.61

Stock options outstanding are as follows:

Range of exercise prices \$	March 31, 2010			December 31, 2009		
	Number	Weighted average remaining life (years)	Weighted average exercise price \$	Number	Weighted average remaining life (years)	Weighted average exercise price \$
0.00 – 0.15	463,329	8.59	0.15	463,329	8.84	0.15
0.84 – 0.96	106,000	4.10	0.87	106,000	4.35	0.87
1.00 – 1.12	95,000	5.81	1.10	95,000	6.06	1.10
1.15 – 1.22	28,000	4.42	1.15	28,000	4.67	1.15
1.25 – 1.50	176,900	4.41	1.33	176,900	4.66	1.33
	869,229			869,229		

During 2010, the Company granted nil (2009 - 233,331) options to purchase common shares. The weighted average fair value of options granted during the period amounted to \$nil (2009 - \$0.12) per option. The fair value of each option granted was determined using the Black-Scholes option pricing model and the following weighted average assumptions:

	March 31 2010	December 31 2009
Risk-free interest rate	2.66%	2.66%
Expected life	10 years	10 years
Expected volatility in the market price of the shares	76.9%	76.9%
Expected dividend yield	-	-

## d) Share warrants

The share warrants outstanding are as follows:

Expiry date	Exercise price \$	March 31 2010	December 31 2009
June 25, 2011	0.25	1,570,983	1,570,983
October 24, 2011	0.25	2,000,000	2,000,000
Balance, end of period		3,570,983	3,570,983

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**12. Information relating to the consolidated statements of earnings**

For the three months ended March 31	2010 \$	2009 \$
a) The following items are included in cost of goods sold:		
Amortization of property, plant and equipment	291,450	332,528
Gain on foreign exchange	(600)	(2,787)
b) The following items are included in operating expenses:		
Amortization of property, plant and equipment	53,550	49,715
Amortization of intangible assets	21,579	15,108
Accretion of interest	25,603	22,253
Interest and bank charges	28,491	20,913
Interest on long-term debt	29,847	45,578
Interest on convertible debentures	192,615	222,195
Loss (gain) on foreign exchange	45,019	(146,844)

**13. Information relating to the consolidated statements of cash flows**

a) Cash flows from operations include interest paid of \$237,527 (2009 - \$128,947).

b) Net change in non-cash working capital items is comprised of the following:

For the three months ended March 31	2010 \$	2009 \$
Accounts receivable	(482,682)	(243,397)
Work-in-progress	408,679	1,076,316
Inventory	16,570	34,255
Investment tax credits receivable	149,471	-
Prepaid expenses	(108,089)	(86,975)
Accounts payable	(116,190)	(127,060)
Deferred revenue	108,596	(1,056,821)
	(23,645)	(403,682)

**14. Capital disclosures**

The Company's objective when managing capital is to maintain adequate cash resources to support planned activities, which include providing analytical, bioanalytical and medical laboratory services. The Company includes shareholders' equity, cash, short-term investments and long term debt in the definition of capital. The Company currently has debt owing to the trade accounts payable, the bank, and the holders of the long-term debt and debentures.

The Company's objective when managing capital is also to maintain financial flexibility in order to preserve its ability to meet financial obligations, including debt servicing payments. Accordingly, the Company had entered into agreements with various lending institutions as described in notes 8, 9 and 10.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**14. Capital disclosures... cont'd**

In managing capital, the Company estimates its future cash requirements by preparing a budget and a multiyear plan annually for review and approval by the Company's Board of Directors. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multiyear plan estimates future activity along with the potential cash requirements and is based on the Company's assessment of its current services along with the expected results from the coming year's activity. Budget to actual variances are prepared monthly and reviewed by the Company's management and are presented quarterly to the Board.

Historically, funding for the Company's plan is primarily managed through the issuance of additional common shares, common share purchase warrants that upon exercise are converted to common shares, private placements from various institutions and the issuance of various debt instruments. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with the Company's progress through its programs, general market conditions, and the availability of capital. There are no assurances that funds will be made available to the Company when required.

**15. Segmented information**

a) For the three months ended March 31, 2010, the Companies operated in the following industries:

	Revenue \$	Net earnings (loss) \$	Amortization \$	Long-term assets \$	Total assets \$
Analytical services	2,867,902	329,025	98,959	2,100,522	4,945,884
Bioanalytical services	895,767	(519,695)	184,187	3,542,284	4,438,336
Medical laboratories	1,268,966	273,178	33,817	2,048,997	2,827,370
Management services	58,035	(879,672)	49,616	1,975,606	2,433,128
	<u>5,090,670</u>	<u>(797,164)</u>	<u>366,579</u>	<u>9,667,409</u>	<u>14,644,718</u>

b) For the three months ended March 31, 2009, the Companies operated in the following industries:

	Revenue \$	Net earnings (loss) \$	Amortization \$	Long-term assets \$	Total assets \$
Analytical services	2,764,763	114,175	115,586	2,466,200	5,290,975
Bioanalytical services	3,590,866	1,881,995	226,662	4,356,612	6,271,258
Medical laboratories	1,126,120	231,713	10,989	1,172,563	1,692,666
Management services	75,906	(1,125,126)	44,114	2,078,910	5,093,331
	<u>7,557,655</u>	<u>1,102,757</u>	<u>397,351</u>	<u>10,074,285</u>	<u>18,348,230</u>

c) Revenues were derived from customers located in the following geographic areas:

For the three months ended March 31	2010 \$	2009 \$
Canada	3,785,842	3,831,166
United States of America	951,416	2,882,163
Rest of the world	353,412	844,326
	<u>5,090,670</u>	<u>7,557,655</u>

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**15. Segmented information... cont'd**

d) Revenues were generated in the following currencies:

For the three months ended March 31	2010 \$	2009 \$
Canadian dollars	4,212,254	4,090,746
U.S. dollars	878,416	3,466,909
Euros	-	-
	5,090,670	7,557,655

**16. Related party transactions**

During the period, the Company paid \$1,000 per month for a total of \$3,000 (2009 - \$3,000), to the Company's Chairman of the Board for his work on specific mandates for the various operating divisions of the Company.

These transactions are measured at the exchange amount, which is the amount of consideration determined and agreed to by the related parties. The Company has a policy that any of the above type of transactions must be approved by the Board of Directors.

**17. Financial instruments****Financial risks**

The Company is exposed to a number of financial risks in the normal course of business operations, including interest rates and foreign currency exchange rates as well as credit risks and liquidity risks. The nature of these risks and the Company's strategy for managing these risks has not changed significantly from the prior period.

**Fair value**

The estimated fair value of certain financial instruments shown on the balance sheet is equivalent to their carrying amount because they are realizable in the short-term or items whose carrying amount approximates the fair value. The financial instruments include cash and cash equivalents, accounts receivable, bank indebtedness and accounts payable.

The fair value of long-term debt approximates market value and corresponds to what the Company would currently obtain for loans with similar maturity dates and terms. Considering the due dates of the long-term debt as at March 31, 2010, the fair value has been established at its carrying amount.

**Credit risk**

The Company, in the normal course of business, monitors the financial condition of its customers and reviews the credit history of each new customer. The Company establishes an allowance for doubtful accounts that corresponds to the credit risks of its specific customers, historical trends and economic circumstances. Individual overdue accounts are reviewed and allowance adjustments are recorded when determined necessary to state receivables at the realizable value. If the financial conditions of customers deteriorate, resulting in their diminished ability or willingness to make payment, additional provisions for doubtful accounts are recorded. The Company's maximum credit risk exposure corresponds to the carrying amounts of the accounts receivable.

The Company's allowance for doubtful accounts is \$45,588 (December 2009 - \$45,588). Of the Company's accounts receivable, \$233,226 (December 2009 - \$506,600) is greater than 90 days. Of this amount, \$48,294 (December 2009 - \$211,942) is included in deferred revenue. Any amounts not provided for are considered to be fully collectable.

**Notes to Interim Consolidated Financial Statements (unaudited)**

March 31, 2010 and 2009

**17. Financial instruments... cont'd**

The Company has one customer which account for approximately 10% of the accounts receivable as at March 31, 2010 (December 2009 - two customers for approximately 22%).

**Interest rate risk**

The Company has a line of credit and a portion of the long-term debt at variable interest rates. Consequently, the Company is exposed to interest rate risk as a result of potential rate fluctuations. A portion of the long-term debt is at fixed interest rates, which are not subject to interest rate fluctuations and accordingly minimizes its interest rate exposure.

**Currency risk**

The Company realizes some of its sales and purchases in foreign currencies. Consequently, it is exposed to fluctuations of these currencies. Assets and liabilities in other currencies are the following:

March 31, 2010	U.S. Dollars	Euros
Cash	182,045	-
Accounts receivable	686,797	-
Work-in-progress	-	-
Accounts payable	195,153	11,842
Deferred revenue	279,832	-

**Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities. The Company manages liquidity risk by forecasting cash flows to identify financing requirements by maintaining committed and demand credit facilities and by maintaining access to additional financing at competitive rates through capital markets and highly rated financial institutions.